FOR IMMEDIATE RELEASE

Media Contact
Nora Ansah
(416) 924-9760
noraansah@can-amhifu.com

CLINICAL TRIAL OFFERS LOCALLY RECURRENT PROSTATE CANCER PATIENTS OPTION FOR TREATMENT WITH HIGH INTENSITY FOCUSED ULTRASOUND

Can-Am HIFU clinic is one of two sites in Canada participating in clinical trial

Toronto, Ontario, November 19, 2009 — Can-Am HIFU clinic is one of several sites in Canada and the U.S. participating in an FDA approved phase III clinical trial to determine the safety and efficacy of HIFU (High Intensity Focused Ultrasound) with the Sonablate® 500 for men with locally recurrent prostate cancer following external beam radiation therapy.

External beam radiation therapy (EBRT) is one of the most common and relied upon primary prostate cancer treatments in Canada. Nonetheless, there is a possibility that prostate cancer may reoccur. One of the few options available to patients with cancer recurrence following EBRT is palliative androgen deprivation therapy. Possible side effects include osteoporosis, anemia, loss of muscle mass, depression, decreased mental acuity and impotence.

"We are pleased and privileged to be able to offer this unique treatment for men experiencing locally recurrent prostate cancer after failed external beam radiation therapy," said Dr. Jack Barkin, lead trial investigator and physician at Can-Am HIFU. "The study will help corroborate pilot-study data which show that HIFU can destroy and potentially "cure" recurrent prostate cancer with just one treatment and without the need for additional hormone therapy."

HIFU is a minimally invasive, outpatient procedure that uses a transrectal probe to focus ultrasound energy creating a sharp increase in heat within the prostate, thus destroying the tissue. HIFU is radiation-free and non-surgical.

Dr. Neil Fleshner, head of urology at Princess Margaret Hospital and Dr. Antonio Finelli, surgeon and urologic oncologist at the University Heath Network, are sub-investigators for the clinical trial. Trial investigators have begun to pre-screen potential candidates; men accepted into the trial will receive treatment at no cost.

To be eligible for the clinical trial, participants must be between the ages of 40-85 and have biopsy-confirmed recurrence of prostate cancer no less than two years following external beam radiation therapy. Additional selection criteria will be discussed in the initial pre-screening process. For more information about enrolling into the trial, please contact the trial coordinator at (416) 256-9606.

HIFU with the Sonablate® 500 is a Health Canada approved treatment. Potential risks of the treatment may include frequency, urgency, mild discomfort or discharge in urinary stream. Less common side effects may also include urinary stricture, retention, incontinence, impotence and rectal fistula.

# # #